Sarcopenic obesity and metabolic syndrome in adult caucasian subjects
Such programs may include mixtures of opioid and nonopioid adjunctive medications, based on evidence from CIPN trials, and also extrapolation from trials in patients with other neuropathic pain syndromes-although such extrapolating must be done with caution, since other syndromes sometimes respond to agents that CIPN does not respond to
J Cardiovasc Pharmacol Ther 15: 41-46
Since its subcellular localization and multimerization appear unaffected during fasting, KIN-19 activity is most likely regulated through cofactor interaction or posttranslational modification
Augmenting brain B 12 with fingolimod or potentially related molecules could enhance both current and future MS therapies. In their paper, the team at Sanford Burnham Prebys, with collaborators at University of Southern California, Juntendo University in Japan, Tokyo University of Pharmacy and Life Sciences and State University of New York, focused on the molecular functioning of FTY720 or fingolimod (Gilenya), a sphingosine 1-phosphate (S1P) receptor modulator that suppresses distribution of T and B immune cells errantly attacking the brains of MS patients